Effectiveness and Safety of Lianhua Qingwen Capsules for COVID-19: A Propensity-Score Matched Cohort Study

Table 2

Associations between Lianhua Qingwen and safety outcomes.

Safety outcome	Crude rate (95% CI, %)	Unadjusted		Adjusted
		OR (95% CI)	-Value	OR (95% CI)	-Value
Acute liver injury
Control	14.0 (12.5-15.5)	1 (ref)		1 (ref)
LHQW	11.5 (10.3-12.8)	0.80 (0.68-0.95)	0.010	0.85 (0.71-1.02)	0.083
Acute kidney injury
Control	5.3 (4.4-6.4)	1 (ref)		1 (ref)
LHQW	3.0 (2.4-3.8)	0.56 (0.42-0.74)	<0.001	0.71 (0.50-1.00)	0.048

LHQW, Lianhua Qingwen capsules; OR, odds ratio; Cl, confidence interval, and ref, reference. Association was adjusted for age, sex, time from symptom onset to admission, severity and symptoms at admission, comorbidities, and antiviral, adrenocortical hormone, and anticoagulant therapy.